Month: August 2023

How Will the Angiographic Catheters Market Transform Itself into a USD 3.85 Billion Powerhouse by 2032?

Written by Customer Service on August 10, 2023. Posted in Mergers And Acquisitions.

Increasing prevalence of cardiovascular diseases is the key factor driving Angiographic Catheters market revenue growth. Vancouver, Aug. 10, 2023 (GLOBE NEWSWIRE) — Emergen research is one of the pioneers in providing strategic insights for emerging and disruptive technologies which are supposed to show exponential growth in the near future., has released a report that delves deep into the dynamic landscape of the Angiographic Catheters Market. Angiographic catheters play a pivotal role in modern healthcare by enabling intricate vascular imaging procedures that aid in diagnosing and treating a wide array of cardiovascular conditions. Angiographic catheters are essential tools used in angiography, a procedure that visualizes blood vessels to detect blockages, aneurysms, and other cardiovascular issues. By combining cutting-edge...

Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia

Written by Customer Service on August 10, 2023. Posted in Public Companies.

Arcutis to receive $30 million upfront payment and is eligible to receive potential development and commercial milestone payments, as well as double digit tiered royaltiesWESTLAKE VILLAGE, Calif. and HANGZHOU, China, Aug. 10, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, and Hangzhou Zhongmei Huadong Pharmaceutical Co, a wholly owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), today announced that the companies have entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast in Greater China (mainland China, Hong Kong, Macau, and Taiwan) and Southeast Asia (Indonesia, Singapore, The Philippines,...

Metalert OEM Manufacturer Begins Shipping into Germany and the U.K. and Increases Production

Written by Customer Service on August 10, 2023. Posted in Public Companies.

LOS ANGELES, CALIFORNIA, Aug. 10, 2023 (GLOBE NEWSWIRE) — Metalert, Inc. (OTC: MLRT) (“the Company”), a pioneer in location sensitive health monitoring devices and wearable technology products announced today Global Safe Tracks, its OEM manufacturer, has received its first production run and started shipping units into Germany and the U.K. Based on the initial positive feedback and forecast, an additional 1,000 devices are going into production. Global Safe Tracks is under license to manufacture a modified version of the GPS SmartSole that includes 2G technology as a fall back to 4G technology for countries where 4G coverage has not been fully implemented. The European version is sold under the brand name “SafeSole” and the made in U.S.A. Cat M1 Bluetooth / Wi-Fi version is sold under the brand name “GPS SmartSole plus.” “We are...

Third Harmonic Bio Announces Second Quarter 2023 Financial Results

Written by Customer Service on August 10, 2023. Posted in Earnings Releases And Operating Results.

Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution, and physicochemical profile U.S. Investigational New Drug (IND) application filing and initiation of clinical trials of THB335 planned for the first half of 2024 Strong financial position with cash and cash equivalents totaling $278.1 million as of June 30, 2023 SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) — Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced financial results for the second quarter ended June 30, 2023. “We are pleased with the speed, rigor and capital efficiency of our team’s efforts this year to advance...

Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update

Written by Customer Service on August 10, 2023. Posted in Earnings Releases And Operating Results.

AUSTIN, Texas, Aug. 10, 2023 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results and business updates for the second quarter of 2023. Eric Poma, PhD., Chief Executive and Chief Scientific Officer of MTEM, stated, “ETBs represent a novel approach to the treatment of cancer with differentiated biology and unique mechanisms of action. We expect to see substantial data across all three of our clinical programs with updates throughout this year and into 2024.” Company HighlightsUp to $40 million Private Placement...

How Will the Aircraft Cabin Interiors Market Transform Itself into a USD 53.85 Billion Powerhouse by 2032?

Written by Customer Service on August 10, 2023. Posted in Mergers And Acquisitions.

Rising demand for affordable, both short- and long-haul airline flights is one of the major factors driving Aircraft Cabin Interiors market revenue growth. Vancouver, Aug. 10, 2023 (GLOBE NEWSWIRE) — Emergen research is one of the pioneers in providing strategic insights for emerging and disruptive technologies which are supposed to show exponential growth in the near future., has released a report that delves deep into the dynamic landscape of the Aircraft Cabin Interiors Market. As organizations seek to enhance their procurement processes and streamline operations, Emergen Research’s latest analysis provides indispensable insights that are poised to revolutionize procurement strategies across industries. The Aircraft Cabin Interiors Market refers to the industry involved in designing, manufacturing, and installing various...

Influenza Diagnostics Market to Surpass 1.46 Billion by 2030 Drives Due to Growth in Influenza Research for Diagnostic Technologies

Written by Customer Service on August 10, 2023. Posted in Mergers And Acquisitions.

SkyQuest projects that the influenza diagnostics market will attain a USD 1.46 billion value by 2030, with a CAGR of 3.5% over the forecast period (2023-2030). The increasing demand for accurate and rapid diagnosis of influenza is driving substantial growth in research for diagnostic technologies. This progress aims to enhance early detection, improve treatment outcomes, and control outbreaks effectively, consequently fueling the expansion of the global influenza diagnostics market. Westford, USA, Aug. 10, 2023 (GLOBE NEWSWIRE) — According to SkyQuest, continuous innovation in diagnostic technologies, such as PCR assays, point-of-care testing, and next-gene sequencing, empowers swift and precise influenza detection. This fuels influenza diagnostics market growth by offering efficient tools for timely diagnosis and informed medical...

MarketWise Reports Financial Results for Second Quarter 2023

Written by Customer Service on August 10, 2023. Posted in Earnings Releases And Operating Results.

~ Total Subscribers of 16.7 Million, Including 750 Thousand Paid Subscribers ~ ~ Revenues of $103.6 Million ~ ~ Billings of $96.2 Million ~ ~ Net Income of $9.7 Million ~ ~ CFFO and Adjusted CFFO of $29.0 Million ~ BALTIMORE, Aug. 10, 2023 (GLOBE NEWSWIRE) — MarketWise, Inc. (NASDAQ: MKTW) (“MarketWise” or the “Company”), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, today reported financial results for second quarter 2023.Second Quarter 2023 Key Performance Highlights YTD YTD YTD(Unaudited) 2Q 2023 2Q 2022 % Change 2Q 2023 2Q 2022 % ChangeTotal Subscribers (in thousands) 16,699 15,871 5.2 % Paid Subscribers (in thousands) 750 898 (16.5 )% Total...

Acorn Achieves Net Income and Positive Cash Flow as Q2 Revenue Rises 22% from Remote Monitoring and Control Solutions for Backup Generators and Gas Pipelines

Written by Customer Service on August 10, 2023. Posted in Earnings Releases And Operating Results.

Investor Call Today at 11am ET – Dial-in # 1-844-834-0644 WILMINGTON, Del., Aug. 10, 2023 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (OTCQB: ACFN), a provider of remote monitoring and control solutions for stand-by power generators, gas pipelines, air compressors and other critical industrial equipment, announced results for its second quarter ended June 30, 2023 (Q2’23). Acorn generated positive net income and cash flow on Q2’23 revenue growth of 22% and cash basis revenue growth of 33%. Acorn is hosting a conference call today at 11:00 a.m. ET (details below).Summary Financial Results ($ in thousands) Q2’23 Q2’22 Change 6M’23 6M’22 ChangeMonitoring revenue $ 1,065 $ 966 +10.2% $ 2,089 $ 1,956 +6.8%Hardware revenue $ 908 $ 655 +38.6% $ 1,633 $ 1,416 +15.3%Total revenue * $ 1,973 $ 1,621 +21.7% $ 3,722 $ 3,372 +10.4%Gross...

MiNK Therapeutics Reports Second Quarter 2023 Results

Written by Customer Service on August 10, 2023. Posted in Earnings Releases And Operating Results.

– Randomized Phase 2 Trial in 2L Metastatic Gastric Cancer Planned to Launch at Memorial Sloan Kettering Cancer Center – iNKT (agenT-797) Data Presented at AACR, ASGCT, and ATS Showed Benefit in Solid Tumor Cancers and in Respiratory Distress – MiNK-215, a Novel FAP-CAR-iNKT Cell Therapy, Eliminated Tumors in NSCLC Models NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today provided a corporate update and reported financial results for the second quarter 2023. “We made significant clinical progress with our lead compound, agenT-797, an allogeneic...

Month: August 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals